Title |
Serious haematological toxicity during and after ipilimumab treatment: a case series
|
---|---|
Published in |
Journal of Medical Case Reports, July 2014
|
DOI | 10.1186/1752-1947-8-240 |
Pubmed ID | |
Authors |
Ester Simeone, Antonio Maria Grimaldi, Assunta Esposito, Marcello Curvietto, Marco Palla, Miriam Paone, Nicola Mozzillo, Paolo Antonio Ascierto |
Abstract |
Immunotherapy with the anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody ipilimumab has been shown to improve overall survival in previously treated and treatment-naïve patients with unresectable stage III or IV melanoma. Consistent with its proposed immunomodulating mechanism of action, the most common toxicities associated with ipilimumab therapy are immune-related in nature and include those related to the skin and gastrointestinal tract, with endocrine and hepatic events also frequent. Other rare adverse events, including haematological aberrations, may also occur and can have serious consequences if unrecognised. Here we describe three patients who developed serious haematological adverse events during or after treatment with ipilimumab. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 1 | 2% |
Unknown | 55 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 7 | 13% |
Student > Ph. D. Student | 7 | 13% |
Researcher | 6 | 11% |
Other | 6 | 11% |
Student > Doctoral Student | 4 | 7% |
Other | 10 | 18% |
Unknown | 16 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 45% |
Agricultural and Biological Sciences | 3 | 5% |
Nursing and Health Professions | 2 | 4% |
Biochemistry, Genetics and Molecular Biology | 2 | 4% |
Neuroscience | 2 | 4% |
Other | 2 | 4% |
Unknown | 20 | 36% |